Inventiva (NASDAQ:IVA) Shares Down 6% – Here’s What Happened

Inventiva S.A. (NASDAQ:IVA)’s share price was down 6% during mid-day trading on Monday . The company traded as low as $2.15 and last traded at $2.21. Approximately 9,217 shares traded hands during trading, a decline of 87% from the average daily volume of 70,537 shares. The stock had previously closed at $2.35.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IVA. HC Wainwright lowered their price objective on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, October 15th. UBS Group initiated coverage on shares of Inventiva in a research note on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target for the company. Finally, Stifel Nicolaus cut their price objective on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Inventiva Stock Down 0.5 %

The firm has a fifty day moving average price of $2.60 and a 200-day moving average price of $2.47.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.